1. Volume 81, Issue 5, Pages 1005-1009 (May 2013)
Relationship Between Body Mass Index and Serum Testosterone Concentration in Patients Receiving Luteinizing Hormone-releasing Hormone Agonist Therapy for Prostate Cancer 
Tim M. van der Sluis, R. Jeroen A. van Moorselaar, Eric J.H. Meuleman, Ronald W. ter Haar, Hong N. Bui, Annemieke C. Heijboer, André N. Vis 
Urology 
Volume 81, Issue 5, Pages (May 2013)
DOI: /j.urology
Copyright © 2013 Elsevier Inc. Terms and Conditions

2. Figure 1
Box plot showing serum total testosterone levels in patients after luteinizing hormone-releasing hormone H agonist therapy measured using isotope dilution-liquid chromatography-tandem mass spectrometry as function of body mass index (BMI). Patient groups classified as normal weight (BMI <25 kg/m2), overweight (BMI kg/m2), or obese (BMI >30 kg/m2). Upper and lower quartiles represented by rectangle; 95% confidence interval by whiskers. Differences between groups were not statistically significant. (Color version available online.)
Urology  , DOI: ( /j.urology )
Copyright © 2013 Elsevier Inc. Terms and Conditions

3. Figure 2
Box plot showing serum sex hormone-binding globulin levels in patients after luteinizing hormone-releasing hormone agonist therapy as function of body mass index (BMI). Upper and lower quartiles represented by rectangle; 95% confidence interval by whiskers. (Color version available online.)
Urology  , DOI: ( /j.urology )
Copyright © 2013 Elsevier Inc. Terms and Conditions

4. Figure 3
Box plot showing serum free testosterone levels in patients after luteinizing hormone-releasing hormone agonist therapy, calculated using algorithm reported by Vermeulen et al19 with fixed albumin concentration of 43 g/L (P <.05 only for obese vs normal weight and overweight). (Color version available online.)
Urology  , DOI: ( /j.urology )
Copyright © 2013 Elsevier Inc. Terms and Conditions